Plain-English translation of NCT06978920 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson Disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing NCR201, a new treatment made from human stem cells that have been grown in the lab and turned into dopamine-producing brain cells. The goal is to inject these cells directly into specific areas of the brain that are damaged in Parkinson's disease, with the hope that they will help restore movement and reduce symptoms. Researchers want to see if this treatment is safe and whether it actually helps patients feel better.
Parkinson's disease damages the brain cells that make dopamine, a chemical needed for smooth movement and control. Current medications help some patients but often lose effectiveness over time, and symptoms get worse as the disease progresses. This treatment aims to replace the damaged cells rather than just mask symptoms, offering a potential new way to help patients who have had Parkinson's for many years.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will undergo an MRI-guided surgical procedure in which doctors inject the stem cells into both sides of your brain using a precise stereotactic navigation system. The trial has two groups receiving different doses of cells to determine which is safest and most effective. You will then be monitored with follow-up visits and imaging scans to track your symptoms, side effects, and whether the treatment is working.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Nuwacell Biotechnologies Co., Ltd.
Enrollment target
~48 participants
Started
June 2025
Primary completion
July 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
40 Years – 75 Years
Last updated on clinicaltrials.gov in August 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.